This internal event is a forum for students, basic, translational and clinical scientists to present their work and brainstorm ideas about new areas for collaborative research.

Webinar link: https://ucsf.zoom.us/webinar/register/WN_fdxl3pKaRL2MpcsUreP45w

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 - 2:05pm</td>
<td>Opening Remarks: <strong>Sabrina Ronen, PhD.</strong></td>
</tr>
<tr>
<td>2:05 - 2:30pm</td>
<td>Translating a Trillion Points of UC Health Data into Therapies, Diagnostics, and New Insights into Disease&lt;br&gt;<strong>Atul Butte, MD PhD</strong></td>
</tr>
<tr>
<td>2:30 - 2:55pm</td>
<td><strong>Rethinking the immune effectors for cancer immunotherapy</strong>&lt;br&gt;<strong>Larry Fong, MD</strong></td>
</tr>
<tr>
<td>3:00 - 3:25pm</td>
<td><strong>Scientific Talks:</strong>&lt;br&gt;3:00 - 3:08pm <em>Exosome Enhanced Immunotherapy &amp; Imaging of Prostate Cancer Response with Hyperpolarized $^{13}$C-MRI</em> - <strong>Robert Bok, MD PhD.</strong>&lt;br&gt;3:08 - 3:16pm <em>Molecular Imaging of Multiple Myeloma Targeting CD46 Using ImmunoPET</em> - <strong>Sinan Wang, PhD.</strong>&lt;br&gt;3:16 - 3:24pm <em>Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion weighted imaging</em> - <strong>Janine Lupo, PhD.</strong></td>
</tr>
<tr>
<td>3:30 - 4:15pm</td>
<td><strong>Power Pitch Breakout Sessions (4 sessions, 4min per pitch)</strong>&lt;br&gt;1. Artificial Intelligence&lt;br&gt;2. Immunotherapy / Theranostics&lt;br&gt;3. Preclinical Cancer Imaging&lt;br&gt;4. Human/Clinical Cancer Imaging&lt;br&gt;<em>See breakout session details below</em></td>
</tr>
<tr>
<td>4:20 - 4:55pm</td>
<td><strong>Keynote Speaker:</strong>&lt;br&gt;<strong>ImmunoPET: Engineered antibodies for imaging immune responses</strong>&lt;br&gt;<strong>Anna Wu, PhD.</strong></td>
</tr>
<tr>
<td>4:55 - 5:00pm</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>
# Power Pitch Breakout Sessions

## 4 Power Pitch Breakout Sessions (4min per pitch)

### Artificial Intelligence
Chair: Janine Lupo, PhD.

1. *Towards higher accuracy mapping of MRI to electron density using a 3D CNN for radiotherapy treatment planning* - **Jessica E Scholey**
2. *A Parsimonious Assessment of Breast Density Classes from Quantitative, AI-based FGT Volume Segmentations* - **Pablo F. Damasceno**, PhD.
3. *Background Parenchymal Enhancement Radiomic Features for Neoadjuvant Treatment Response Prediction in Breast Cancer Patients* - **Alex Nguyen**
4. *Early prediction of progression free survival (PFS) and overall survival (OS) of patients with glioblastoma using machine learning and multi-parametric MRI* - **Nhat Tran**
5. *Clinically Integrated Validation of Automated Glioma Progression Detection via Deep Learning* - **Pablo F. Damasceno**, PhD.
6. *Improving the generalizability of convolutional neural networks for T2-lesion segmentation of gliomas in the post-treatment setting* - **Jacob Ellison**
7. *3D Y-Net for Mixed-Supervision of Prostate Cancer Detection, Localization, and Classification from MRI* - **Abhejit Rajagopal**, PhD.
8. *Subtype-specific MRI models to guide selection of candidates for de-escalation of neoadjuvant therapy* - **Wen Li**, PhD.

### Immunotherapy / Theranostics
Chair: Robert Flavell, MD PhD.

1. *Proteomic profiling of the cellular surface-ome reveals new targets for potential theranostic applications in cancers driven by TERT promoter mutations* - **Zhuo Chen**, PhD.
2. *Incidence of sarcoidosis-like reaction in patients treated with immunotherapy* - **Yan Li**, MD.
3. *Targeting CUB domain containing protein 1 (CDCP1) for cancer theranostics* - **Shalini Chopra**, PhD.
4. *Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron Targeted Cancer Therapies* - **Ning Zhao**, PhD.
5. *Development of Prostate-Specific Membrane Antigen Targeted Theranostic Nanoparticles to Treat Prostate Cancer Using Boron Neutron Capture Therapy* - **Niranjan Meher**, PhD.
6. *Potentiation of PSMA Radioligand Therapy by PARP Inhibition* - **Tanu Shenoy**, PhD.
7. *89Zr-fresolimumab PET imaging to localize TGFβ activation in glioblastoma* - **Oliver Reiners**, PhD.
8. *A novel system for in-vivo imaging of Ac-225* - **Javier Caravaca**, PhD.
9. *Impact of cellularity and heterogeneity on deposited absorbed dose patterns of alpha and beta emitters in a model of tumoral clusters* - **Jonathan Tranel**, PhD.
1. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers - Yung-Hua Wang

2. Deuterium metabolic imaging of tumor burden and response to therapy in mutant IDH gliomas in vivo - Celine Taglang, PhD.

3. MRS based biomarkers of IDH1 mutant glioma response to the IDH inhibitor BAY-1436032 - Donghyun Hong, PhD.

4. Deuterium magnetic resonance spectroscopy using 2H-pyruvate allows non-invasive in vivo imaging of TERT expression in brain tumors - Georgios Batsios, PhD.

5. Metabolic signatures of TERT positive human glioblastoma detected by MR spectroscopy - Noriaki Minami, PhD.

6. Magnetic Resonance Imaging Comparisons of Renal Cell Carcinoma Patient-derived Xenografts - Joao Piraquive Agudelo, PhD.

7. Optimization of Hyperpolarized Carbon-13 pH Imaging Methods in Preparation for Clinical Translation in Prostate Cancer - Changhua Mu, PhD.

8. Hyperpolarized 13C MR imaging of prostate cancer patient derived xenograft models and their response to therapy - Shubhangi Agarwal, PhD.

9. Prostate cancer patient-derived xenograft model development and MR imaging characterization - Emilie Decavel-Bueff

---


2. Multi-parametric hyperpolarized 13C/1H imaging of human gliomas expressing diverse pathologic mutations - Adam Autry, PhD.

3. Variable Resolution Hyperpolarized [2-13C]Pyruvate MRI in Healthy Volunteers and Patients with IDH-Mutant Glioma - Sana Vaziri, PhD.

4. Hyperpolarized 13C Metabolic Imaging of Patients with Pancreatic Ductal Adenocarcinoma - Jeremy Gordon, PhD.

5. Quantifying Renal Cell Carcinoma Metabolism with metabolite-specific bSSFP hyperpolarized [1-13C]pyruvate MR - Sule Sahin

6. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk - Mark Jesus Magbanua, PhD.

7. Neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL: Radiologic review of breast MRI to refine selection of candidates for therapy de-escalation - Natsuko Onishi, PhD.

8. Relationship of dedicated breast PET and MRI features in breast cancer patients receiving neoadjuvant chemotherapy - Deep K. Hathi, PhD.